@article{0aff69bb314b44deb3065d445bc38fae,
title = "EAACI Biologicals Guidelines-Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old",
abstract = "Chronic spontaneous urticaria (CSU) imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity and insufficient efficacy of classical drugs such as H1 R-antihistamines. Better understanding of the mechanisms has enabled a stratified approach to the management of CSU, supporting the use of targeted treatment with omalizumab. However, many practical issues including selection of responders, the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home-based) and its cost-effectiveness still require further clarification. The EAACI Guidelines on the use of omalizumab in CSU follow the GRADE approach in formulating recommendations for each outcome. In addition, future therapeutic approaches and perspectives as well as research priorities are discussed.",
keywords = "Adolescent, Adult, Anti-Allergic Agents/therapeutic use, Biological Products/therapeutic use, Child, Chronic Disease, Chronic Urticaria, Humans, Omalizumab/therapeutic use, Treatment Outcome, Urticaria/drug therapy",
author = "Ioana Agache and Akdis, {Cezmi A} and Mubeccel Akdis and Knut Brockow and Tomas Chivato and {Del Giacco}, Stefano and Thomas Eiwegger and Kilian Eyerich and Ana Gim{\'e}nez-Arnau and Jan Gutermuth and Emma Guttman-Yassky and Marcus Maurer and Graham Ogg and Ong, {Peck Y} and Liam O'Mahony and J{\"u}rgen Schwarze and Amena Warner and Thomas Werfel and Oscar Palomares and Marek Jutel",
note = "Funding Information: The GDG is grateful to all the methodology team from the Iberoamerican Cochrane Center (Biomedical Research Institute Sant Pau) who conducted the systematic reviews for efficacy, safety and economic evidence. Funding Information: IA serves as associate editor of Allergy. CA reports grants from Allergopharma, Idorsia, Swiss National Science Foundation, Christine K{\"u}hne‐Center for Allergy Research and Education, European Commission Horizon 2020 Framework Programme, Cure, Novartis Research Institutes, Astra Zeneca, Scibase, and is on the Sanofi/Regeneron advisory board. MA declares grants from Allergopharma, Idorsia, Swiss National Science Foundation, Christine K{\"u}hne‐Center for Allergy Research and Education, European Commission's Horizon's 2020 Framework Programme, Cure, Novartis Research Institutes, AstraZeneca, Scibase and other from Sanofi/Regeneron. KB has received personal fees from Novartis. SG reports personal fees from AstraZeneca, GSK and Novartis. TE has received grants or other from DBV, Innovation Fund Denmark, Regeneron, the Allergy and Anaphylaxis Program SickKids; serves as associate editor for Allergy and in the local advisory board of ALK. KE reports grants and/or personal fees from AbbVie, BMS, Boehringer Ingelheim, Lilly, LEO, Janssen, grants from Galapagos, UCB, Novartis and Sanofi. G‐AA reports grants and/or personal fees from Novartis, Uriach Pharma, GSK, Regeneron Sanofi, Instituto Carlos III FEDER, Leo‐Pharma, Almirall, Amgen, Menarini and MSD. JG declares grants and/or personal fees from Sanofi‐Regeneron, Novartis, AbbVie, Janssen, LEO Pharma, L{\textquoteright}Or{\'e}al and Mylan, and has been issued a patent. MM reports grants and/or personal fees from Sanofi/Regeneron, Allakos, Alnylam, Amgen, Aralez, ArgenX, AstraZeneca, BioCryst, Blueprint, Celldex, Centogene, CSL Behring, Dyax, FAES, Genentech, Ginnovation, Innate Pharma, Kalvista, Kyowa Kirin, Leo Pharma, Lilly, Menarini, Moxie, Novartis, Pharming, Pharvaris, Roche, Shire/Takeda, Third HarmonicBio, UCB and Uriach. GO reports personal fees, grants and/or non‐financial support from the University of Oxford, Sanofi, Celgene, Novartis, Janssen, Orbit, UCB, AnaptysBio, Eli Lilly and Orbit Discovery. PO reports grants and others from Regeneron, Pfizer, AbbVie and Incyte. LOM has received grants from GSK and personal fees from AHL. AW declares no personal conflict of interest but her organization AllergyUK has received fees from Sanofi. OP received research grants from Inmunotek S.L. and Novartis; received fees for giving scientific lectures from Allergy Therapeutics, Amgen, AstraZeneca, Diater, GSK, Inmunotek S.L, Novartis, Sanofi‐Genzyme and Stallergenes; participated in advisory boards from Novartis and Sanofi‐Genzyme. MJ reports personal fees from ALK‐Abello, Allergopharma, Stallergenes, Anergis, Allergy Therapeutics, Circassia, Leti, Biomay, HAL, AstraZeneca, GSK, Novartis, Teva, Vectura, UCB, Takeda, Roche, Janssen, MedImmune and Chiesi. TC, EG‐Y, JS and TW have no conflict of interest within the scope of the submitted work. Publisher Copyright: {\textcopyright} 2021 European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.",
year = "2022",
month = jan,
doi = "10.1111/all.15030",
language = "English",
volume = "77",
pages = "17--38",
journal = "Allergy: European Journal of Allergy and Clinical Immunology",
issn = "0105-4538",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "1",
}